about
Overview of asbestos issues in KoreaDownregulated microRNAs in the differential diagnosis of malignant pleural mesotheliomaCD30 is a potential therapeutic target in malignant mesotheliomaPeritoneal mesothelioma: a reviewRepeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomesPrimary Peritoneal Mesothelioma Resulting in Small Bowel Obstruction: A Case Report and Review of LiteratureAsbestos in AsiaCurrent investigations into the genotoxicity of zinc oxide and silica nanoparticles in mammalian models in vitro and in vivo: carcinogenic/genotoxic potential, relevant mechanisms and biomarkers, artifacts, and limitationsHippo/YAP pathway for targeted therapyClinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusionsDistinct affinity of nuclear proteins to the surface of chrysotile and crocidolitePerspectives on refractory ceramic fiber (RCF) carcinogenicity: comparisons with other fibersAsbestos exposure predicts cell cycle control gene promoter methylation in pleural mesotheliomaIncreased efficacy of doxorubicin delivered in multifunctional microparticles for mesothelioma therapyAwareness of Asbestos and Action Plans for Its Exposure can Help Lives Exposed to AsbestosAssociation of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesotheliomaSyntenic relationships between genomic profiles of fiber-induced murine and human malignant mesotheliomaAsbestos and erionite prime and activate the NLRP3 inflammasome that stimulates autocrine cytokine release in human mesothelial cellsCREST biorepository for translational studies on malignant mesothelioma, lung cancer and other respiratory tract diseases: Informatics infrastructure and standardized annotationFibulin-3 as a biomarker of response to treatment in malignant mesotheliomaEpigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcomeCellular and molecular parameters of mesotheliomaNanomaterials toxicity and cell death modalitiesAsbestos-induced lung diseases: an updateGlobal mesothelioma deaths reported to the World Health Organization between 1994 and 2008Occupational exposure to carcinogens: Benzene, pesticides and fibers (Review)Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathwaysAssessing nanotoxicity in cells in vitroLocalized malignant pleural sarcomatoid mesothelioma misdiagnosed as benign localized fibrous tumorCurcumin: a double hit on malignant mesotheliomamiR-1 induces growth arrest and apoptosis in malignant mesotheliomaCharacterisation of mesothelioma-initiating cells and their susceptibility to anti-cancer agentsSpecific expression of human intelectin-1 in malignant pleural mesothelioma and gastrointestinal goblet cellsMesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cellsModern management of malignant pleural mesotheliomaA 26-year-old male with mesothelioma due to asbestos exposure.Differentiation of lung adenocarcinoma, pleural mesothelioma, and nonmalignant pulmonary tissues using DNA methylation profiles.Assessing model fit in joint models of longitudinal and survival data with applications to cancer clinical trials.Wide complex ventricular tachycardia presenting sign of metastatic pleural mesotheliomaPemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.
P2860
Q22305627-F05C9E02-1E37-4399-A3E7-661E51543804Q23913270-6AFACFA2-63DB-43B5-8AA4-F8B94F1EB8CBQ23921491-B646EFA7-2699-40AE-BC5E-DE3F07649A21Q24680847-90181B0F-A398-45F8-BF23-EE6FA5A9BAEDQ26768299-81FA34C4-4DFC-45A3-BB9B-1AA0A963616AQ26801782-7BD64382-F212-4993-A44D-39180C7F9AC2Q28087504-0BFCAC2C-F064-4DA7-884D-B225F5FF7C3AQ28087733-0E168931-F5CA-4265-94AA-639C9FFC4B35Q28088294-887E32B1-0D23-4BA4-BA58-0EFD2C008364Q28238665-EE93D59C-C32C-49BB-B49D-9BE95BFA2037Q28364944-8A0A83EE-A9FF-4CBD-BA37-056546FAD84FQ28383101-F33DC718-1680-4769-AD8F-D26331000EBAQ28385230-32AE22D0-AF52-4749-AC5E-ED300C91A95EQ28385656-990C1C17-20F7-41E3-BB24-C43F7F6F9AABQ28386762-5C5BD3B0-0971-4A23-85E1-85C5FDBF3004Q28387413-9573D6C6-F929-400D-A7AA-6708CCFC4FE0Q28387443-6140DC0F-8BCD-4E96-879F-D0AC3B39736DQ28387699-4E0FA650-20C5-4748-89A2-0B1BB58B3ADDQ28388422-5EA23D41-403C-4442-9888-8C05C3BC08D5Q28389185-8C065742-D5B2-4AD1-ADBC-1EA3EFFEAEBAQ28391055-D42DD1E6-E62F-43ED-B234-ED992F287676Q28391676-7F752D86-C93F-464D-AB35-77AAA339E0B1Q28392044-05C5AD69-5AD8-4EB5-A429-CCB4785BA31EQ28393032-6DC2F583-AB5F-44AB-95FD-530EAFDA953BQ28393456-0DC4983F-D8EB-48CC-8ADC-ABEEC12D8190Q28393587-3D8FABB3-DD51-4105-A0DC-F99FB37131D5Q28393611-947EF65C-EAB5-4C1B-93A8-58C1D462E606Q28394837-6C10D883-3E17-4F70-978A-5AB13197942DQ28395488-A95AA48F-0064-4E16-876A-EB57D48CECDEQ28397518-6A0F23CC-C4E9-41DC-9DB9-888F62A54FB0Q28397782-706A29DA-9571-422A-94E7-119BFFBCFBCDQ28546911-1F44092D-5678-4CA6-8FAA-826DEA64F251Q28727626-37B4FAEF-8C64-41B4-AAF7-31E6D73DF98EQ29048401-03BE6BA1-7E7B-4EA8-AD92-D1D4AAE6830EQ29248127-0FEA6E38-BE36-405C-8F08-E06C55F20D4BQ30474771-14AD2F3E-2216-4075-9D91-99BD0E0A17A2Q30490697-6951E043-FF5B-4951-AE61-8667C6FF9052Q30837515-CCBFB863-EB34-4FFF-8490-0854B5EB9BA5Q33164204-2CCBD277-67F4-46B4-9924-C0B11DC05851Q33379936-483C958D-7F7D-449E-90FA-5D21D353B2FC
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Advances in malignant mesothelioma.
@ast
Advances in malignant mesothelioma.
@en
Advances in malignant mesothelioma.
@nl
type
label
Advances in malignant mesothelioma.
@ast
Advances in malignant mesothelioma.
@en
Advances in malignant mesothelioma.
@nl
prefLabel
Advances in malignant mesothelioma.
@ast
Advances in malignant mesothelioma.
@en
Advances in malignant mesothelioma.
@nl
P356
P1476
Advances in malignant mesothelioma.
@en
P2093
Bruce W S Robinson
Richard A Lake
P304
P356
10.1056/NEJMRA050152
P407
P577
2005-10-01T00:00:00Z